Kolon Life Science Inc Cash Flow-to-Debt Ratio
Kolon Life Science Inc cash flow-to-debt ratio. Kolon Life Science Inc (102940) has a Cash Flow-to-Debt Ratio of 0.01x as of September 2025, meaning its operating cash flow of ₩2.58 Billion could theoretically repay 0% of its total liabilities (₩295.72 Billion) in one year. Check earnings quality score of Kolon Life Science Inc to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Kolon Life Science Inc (2014–2024)
Cash flow-to-debt ratio of Kolon Life Science Inc from 2014 to 2024. Historical debt coverage capacity for Kolon Life Science Inc across 11 annual periods. Check Kolon Life Science Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Kolon Life Science Inc Cash Flow-to-Debt Ratio by Year (2014–2024)
Kolon Life Science Inc cash flow-to-debt ratio by year from 2014 to 2024. Year-by-year debt coverage analysis for Kolon Life Science Inc. For the full cash flow conversion analysis, see Kolon Life Science Inc cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.05x | ₩-14.08 Billion | ₩270.23 Billion | ▲ +64.0% |
| 2023 | -0.14x | ₩-24.87 Billion | ₩171.76 Billion | ▼ -1.6% |
| 2022 | -0.14x | ₩-20.85 Billion | ₩146.39 Billion | ▼ -19.0% |
| 2021 | -0.12x | ₩-16.19 Billion | ₩135.25 Billion | ▼ -211.8% |
| 2020 | -0.04x | ₩-7.31 Billion | ₩190.38 Billion | ▲ +66.3% |
| 2019 | -0.11x | ₩-20.18 Billion | ₩177.27 Billion | ▼ -44.6% |
| 2018 | -0.08x | ₩-13.60 Billion | ₩172.76 Billion | ▼ -62.7% |
| 2017 | -0.05x | ₩-8.29 Billion | ₩171.38 Billion | ▼ -116.3% |
| 2016 | 0.30x | ₩28.11 Billion | ₩94.78 Billion | ▲ +32.8% |
| 2015 | 0.22x | ₩20.81 Billion | ₩93.17 Billion | ▲ +34.3% |
| 2014 | 0.17x | ₩12.10 Billion | ₩72.72 Billion | — |